The Egyptian International Pharmaceuticals Industries Company (EIPICO) plans to invest approximately $33 million in constructing a full-cycle biopharmaceutical plant in Kazakhstan. According to the Ministry of Healthcare, the plant will produce highly similar copies of existing biological drugs called biosimilars and cancer treatment medications.
The project is expected to create around 200 jobs for Kazakhstani citizens. The ministry stated that the plant’s construction «will strengthen Kazakhstan’s position in the pharmaceutical sector, contributing to the localization of essential drug production.»
Earlier this spring, Madina Abdikadyr, a representative of the national company Kazakh Invest, met with Ahmad Kilani, chairman of EIPICO. At...